由于大多数 T 细胞淋巴瘤缺乏 CD20 表达，因此表现出异常 CD20 表达的蕈样肉芽肿 (MF) 病例极为罕见。我们旨在全面评估 7 例诊断为 CD20 阳性 MF 的患者的临床、组织病理学和预后特征。这项回顾性研究检查了 7 例 CD20 表达异常的 MF 病例。该研究提供了人口统计、临床特征、组织病理学和治疗结果的详细信息。关键时间点包括 MF 的初步诊断、CD20 表达检测和随访，平均随访 46 个月。异常 CD20 阳性 MF 被诊断的平均年龄为 58.6 岁，距首次 MF 诊断约 5.6 年。 CD20检测后，患者出现疾病晚期，需要化疗、brentuximab vedotin和同种异体造血干细胞移植等治疗。 4 名患者死于淋巴瘤，平均生存时间为 52 个月。 MF 中 CD20 异常表达很少见，但表明病程进展，且预后不良。这通常需要全身化疗，在某些情况下还需要同种异体造血干细胞移植。这项研究为 CD20 表达异常的 MF 患者的临床特征、疾病进展和治疗选择提供了重要见解。有必要进行进一步的研究来验证新兴疗法的有效性，并增强我们对这一独特 MF 亚组特有的潜在机制和预后决定因素的理解。© 作者 2024。由牛津大学出版社代表英国皮肤科医师协会出版。版权所有。如需商业重复使用，请联系 reprints@oup.com 获取转载和转载的翻译权。所有其他权限都可以通过我们网站文章页面上的权限链接通过我们的 RightsLink 服务获得 - 如需了解更多信息，请联系journals.permissions@oup.com。

As the majority of T-cell lymphomas lack CD20 expression, cases of mycosis fungoides (MF) exhibiting aberrant CD20 expression are exceedingly uncommon.We aim to comprehensively evaluate the clinical, histopathological, and prognostic features of 7 patients diagnosed with CD20-positive MF.This retrospective study examines seven cases of MF with aberrant CD20 expression. The study provides details of demographics, clinical features, histopathology and treatment outcomes. Key time points include initial diagnosis of MF, detection of CD20 expression and follow-up, with a mean follow-up of 46 months.Aberrant CD20-positive MF was diagnosed at an average age of 58.6 years, approximately 5.6 years after first MF diagnosis. Following CD20 detection, patients presented with advanced disease stages, requiring treatments such as chemotherapy, brentuximab vedotin, and allogeneic hematopoietic stem cell transplantation. Four patients died from lymphoma, with an average survival time of 52 months.Aberrant CD20 expression in MF is rare but indicates a progressive course associated with poor prognosis. This often requires systemic chemotherapy and, in certain instances, allogeneic hematopoietic stem cell transplantation. This study provides important insights into the clinical attributes, disease progression, and treatment options for MF patients with aberrant CD20 expression. Further research is necessary to validate the effectiveness of emerging therapies and enhance our understanding of the underlying mechanisms and prognostic determinants specific to this unique MF subgroup.© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.